Improvement of quality of life and symptom burden after robot-assisted radical prostatectomy in patients with moderate to severe LUTS.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 08 2021
18 08 2021
Historique:
received:
28
04
2021
accepted:
23
07
2021
entrez:
19
8
2021
pubmed:
20
8
2021
medline:
12
11
2021
Statut:
epublish
Résumé
The aim of this study was to assess clinically meaningful differences of preoperative lower urinary tract symptoms (LUTS) and quality of life (QoL) before and after robot-assisted radical prostatectomy (RARP). Therefore we identified 5506 RARP patients from 2007 to 2018 with completed International Prostate Symptom Score (IPSS) and -QoL questionnaires before and 12 months after RARP in our institution. Marked clinically important difference (MCID) was defined by using the strictest IPSS-difference of - 8 points. Multivariable logistic regression analyses (LRM) aimed to predict ∆IPSS ≤ - 8 and were restricted to RARP patients with preoperatively moderate (IPSS 8-19) vs. severe (IPSS 20-35) LUTS burden (n = 2305). Preoperative LUTS was categorized as moderate and severe in 37% (n = 2014) and 5.3% of the complete cohort (n = 291), respectively. Here, a postoperative ∆IPSS ≤ - 8, was reported in 38% vs. 90%. In LRM, younger age (OR 0.98, 95%CI 0.97-0.99; p = 0.007), lower BMI (OR 0.94, 95%CI 0.92-0.97; p < 0.001), higher preoperative LUTS burden (severe vs. moderate [REF.] OR 15.6, 95%CI 10.4-23.4; p < 0.001), greater prostate specimen weight (per 10 g, OR 1.12, 95%CI 1.07-1.16; p < 0.001) and the event of urinary continence recovery (OR 1.66 95%CI 1.25-2.21; p < 0.001) were independent predictors of a marked LUTS improvement after RARP. Less rigorous IPSS-difference of - 5 points yielded identical predictors. To sum up, in substantial proportions of patients with preoperative moderate or severe LUTS a marked improvement of LUTS and QoL can be expected at 12 months after RARP. LRM revealed greatest benefit in those patients with preoperatively greatest LUTS burden, prostate enlargement, lower BMI, younger age and the event of urinary continence recovery.
Identifiants
pubmed: 34408175
doi: 10.1038/s41598-021-95525-2
pii: 10.1038/s41598-021-95525-2
pmc: PMC8373967
doi:
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16757Informations de copyright
© 2021. The Author(s).
Références
Urology. 2013 Apr;81(4):787-93
pubmed: 23434100
Anticancer Res. 2016 Sep;36(9):4895-901
pubmed: 27630346
Prostate Cancer Prostatic Dis. 2020 Sep;23(3):465-474
pubmed: 32029929
BJU Int. 2013 Nov;112(7):936-43
pubmed: 23937206
Prostate Cancer Prostatic Dis. 2019 May;22(2):317-323
pubmed: 30410016
Neurourol Urodyn. 2018 Jan;37(1):322-330
pubmed: 28452451
J Urol. 2011 Dec;186(6):2316-22
pubmed: 22014824
J Urol. 2014 Mar;191(3):715-21
pubmed: 24076306
Prostate Cancer Prostatic Dis. 2021 Mar;24(1):69-76
pubmed: 32152437
Eur Urol. 2013 Mar;63(3):506-16
pubmed: 23018163
Eur Urol. 2010 Jul;58(1):149-56
pubmed: 20356669
World J Urol. 2013 Jun;31(3):673-82
pubmed: 22940773
Transl Androl Urol. 2019 Aug;8(4):320-328
pubmed: 31555555
Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1152-1161
pubmed: 30617074
Neurourol Urodyn. 2004;23(4):322-30
pubmed: 15227649
Urol Oncol. 2018 Aug;36(8):364.e15-364.e22
pubmed: 29891407
Nat Rev Urol. 2013 Jan;10(1):49-54
pubmed: 23165396
World J Urol. 2019 Mar;37(3):469-479
pubmed: 29992380
Eur Urol. 2012 Sep;62(3):405-17
pubmed: 22749852
J Urol. 1995 Nov;154(5):1770-4
pubmed: 7563343
Eur Urol. 2014 Jun;65(6):1171-7
pubmed: 23587869
Eur Urol. 2012 Jan;61(1):78-84
pubmed: 21945718
BJU Int. 2019 May;123 Suppl 5:47-53
pubmed: 31012991
Prostate Cancer Prostatic Dis. 2021 Mar;24(1):77-80
pubmed: 32296126
BJU Int. 2012 Aug;110(4):540-5
pubmed: 22243806
Urology. 2003 Jun;61(6):1086-91
pubmed: 12809866
Neurourol Urodyn. 2019 Apr;38(4):1067-1075
pubmed: 30995359
J Endourol. 2008 Feb;22(2):369-76
pubmed: 18294044
J Urol. 2004 Mar;171(3):1216-9
pubmed: 14767305
Curr Urol Rep. 2020 Jul 1;21(9):32
pubmed: 32607874
Eur Urol. 2012 Apr;61(4):664-75
pubmed: 22169079
Urol Oncol. 2021 Mar;39(3):192.e7-192.e14
pubmed: 32861619
BJU Int. 2015 May;115(5):815-21
pubmed: 25195970
Sci Rep. 2021 Feb 11;11(1):3632
pubmed: 33574414